The ecto-nucleotide pyrophosphatase/phosphodiesterase (NPP) family of proteins mediates purinergic signaling by degrading extracellular nucleotides and also participates in phospholipid metabolism. NPP5 (ENPP5) is the least characterized member of this group and its specific role is unknown. This enzyme does not display activity on certain nucleotides and on other typical NPP substrates. In order to gain insights into its function, we determined the crystal structure of human and murine NPP5. Structural comparison with close homologs revealed a key phenylalanine to tyrosine substitution that prevents efficient hydrolysis of nucleotide diphosphates and triphosphates; reversal of this mutation enabled degradation of these molecules. Interestingly, NPP5 is able to cleave nicotinamide adenine dinucleotide (NAD), suggesting a potential role of this enzyme in NAD-based neurotransmission. An NPP5-specific metal binding motif is found adjacent to the active site, although its significance is unclear. These findings expand our understanding of substrate specificity within the NPP family.
Introduction
Extracellular nucleotides are important mediators of signal transmission between cells, with roles ranging from neurotransmission to inflammation and hemostasis. When secreted, these molecules bind to and activate purinergic receptors. Their action can be modulated or terminated by ecto-nucleotidases, a class of proteins with numerous members and overlapping specificities [1] . One major family of enzymes with roles in purinergic signaling are the ecto-nucleotide pyrophosphatases/ phosphodiesterases (NPPs) [2] . Seven NPPs are found in mammals. NPP1 is located on the surface of osteoblasts and chondrocytes where it cleaves NTPs to generate pyrophosphate, an inhibitor of bone mineralization [3, 4] . NPP3 (CD203c) is expressed on the cell membrane of basophils and mast cells and degrades ATP to downregulate inflammation [5] . NPP4 is present on brain vascular endothelium and participates in hemostasis by converting diadenosine triphosphate to ADP, which induces platelet aggregation [6] . In contrast to these enzymes acting on extracellular nucleotides, other NPPs degrade phospholipids or related molecules. NPP2 (autotaxin) converts lysophosphatidylcholine to lysophosphatidic acid, a signal mediator that stimulates cell survival, proliferation, differentiation, and migration [7, 8] . NPP6 participates in choline metabolism, with glycerophosphocholine as the proposed substrate [9] , whereas NPP7 (alkaline sphingomyelinase) digests dietary sphingomyelin in the intestines [10] .
The remaining family member, NPP5 (ENPP5), a type I transmembrane protein, is poorly characterized and its specific functions and substrates are unknown. It is highly expressed in the human brain, respiratory epithelium, and epididymis and in the murine brain, kidneys, and white adipose tissue [11, 12] . NPP5 knockout mice display decreased serum insulin levels as the main phenotype [13] , and expression of this gene is lowered twofold in both type 2 diabetes mellitus and Alzheimer's disease patients, as one of 18 genes differentially regulated in both conditions [14] . NPP5 is upregulated 2-to 14-fold in all brain regions in a high anxiety-related behavior mouse line versus their lowanxiety counterparts [15] , as one of 13 differentially expressed genes found in the study. This enzyme was also identified as a substrate of beta-secretase 1 (BACE1), a membrane protease that also cleaves the amyloid precursor protein and other targets [16] . Processing by BACE1 releases NPP5 into the CSF in mice and in vitro [16] . Glycosylation of this enzyme may be of particular importance, as it was one of three proteins found bearing high-mannose glycans in the rat brain [11] . This glycosylation type is rare on mature proteins in mammalian cells, and NPP5 may thus play a role in neuronal cell binding or recognition [11] . Furthermore, glycosylation of this enzyme is significantly decreased in a mouse model of Rett syndrome, a neurodevelopmental disorder [17] . These findings point to a potential metabolic or neural role for NPP5.
In contrast, it was identified as an angiogenesisrelated gene in pediatric high-grade glioma [18] . Orthologs of this enzyme have been reported in the salivary tissue of the vampire snail which feeds on the blood of fish [19] and in parasitic flatworms that live in blood capillaries [20] [21] [22] . Metabolism of nucleotides in the circulation was proposed as a function for these homologs. Surprisingly, mammalian NPP5 is inactive against the nucleotidase substrate p-nitrophenyl-TMP [11] and against phospholipids and related compounds [11, 23] . To gain insights into functions of this protein, we determined the crystal structure of human and murine NPP5. Structural and enzymatic analyses reveal NPP5-specific features that prevent efficient hydrolysis of NTPs and NDPs, while allowing cleavage of other nucleotides such as NAD.
Results and Discussion

Overall structure
We determined the 1.5
A-resolution crystal structure of the murine NPP5 and the 2. 6 A structure of its human counterpart (85% identity). The crystallized constructs comprise residues 25-430, excluding the N-terminal signal peptide [11] and the C-terminal portion which contains a transmembrane helix and a short cytoplasmic segment. Residues 400-430 likely form a flexible linker to the membrane, lacking sequence conservation and disordered in the structure.
NPP5 is composed of a catalytic domain with an inserted 'cap' subdomain (Fig. 1A) . At the core of the catalytic domain is an eight-stranded mixed b-sheet flanked by four a-helices on both faces. This a-b-a fold classifies the protein into the alkaline phosphatase superfamily (CATH ID: 3.40.720.10). The cap subdomain comprises residues 243-336 and consists of four antiparallel b-strands along with two smaller strands, two short helices, and long loop segments at the extensive interdomain interface. The cap is specific to the NPP family (PFAM ID: PF01663) which is subdivided into two groups: the single-domain enzymes NPP4-7 and the larger proteins NPP1-3 which also contain a nuclease-like domain and two somatomedin B-like units [1] . The crystal structures of NPP1 [3, 4] , NPP2 [7, 8] , NPP4 [6] , NPP6 [9] , and NPP7 [10] are known, and the secondary structure elements are well-conserved within the catalytic domain (Fig. 1B) . NPP5 contains no disulfide bonds and possesses eight N-linked glycosylation sites, seven of which bear glycans visible in the structures, whereas the eighth Asn-362 sequon is surfaceexposed but unmodified in the recombinant protein.
Active site
The catalytic center of NPP5 consists of two zinc ions held by the side chains of seven residues (Fig. 1C) . Zn1 is coordinated by Asp-191 (bidentate), His-195, and His-339, while Zn2 is bound by Asp-36 (bidentate), Thr-72, Asp-238, and His-239. This arrangement is conserved in the NPP family (Fig. 1D) . The proposed reaction mechanism involves positioning of the substrate phosphate moiety at the zinc ions, nucleophilic attack by Thr-72 on the phosphorus atom with departure of a leaving group, and subsequent hydrolysis of the covalent intermediate to release the second product [2] . Interestingly, the crystal structure revealed a third zinc ion adjacent to the active site, coordinated by the side chains of Glu-159 and Asp-192 (Fig. 1C , E). Zn3 is not found in structures of the other NPPs ( Fig. 1D ) and is not expected to be present in NPP3 either, as the two anionic residues are NPP5-specific. The proximity of Zn3 to the active site raised the possibility of an involvement in substrate recognition.
Substrate binding
Sequence comparison places NPP5 in the nucleotide phosphodiesterase category of NPPs, with 53% identity to NPP4, 36% to NPP1, and 35% to NPP3. However, this enzyme's substrates are unknown, as it cannot cleave lysophosphatidylcholine or glycerophosphocholine [11, 23] and, surprisingly, is also inactive on the nucletotide p-nitrophenyl-TMP [11] . In order to rationalize the lack of activity against nucleotides, the substrate binding cavity on the surface of NPP5 was compared with that of NPP4 and NPP1 in complex with AMP [4, 6] (Fig. 2A) . These two proteins establish p-p stacking with their substrates by wedging the nucleobase between a tyrosine and a phenylalanine residue, with further van der Waals contacts to a nearby loop. The sequence of this loop diverges in the three proteins. In addition, the phenylalanine residue which forms a T-shaped p-p stacking interaction with AMP in NPP4 and NPP1 is replaced by Tyr-73 in NPP5. The Tyr-73 oxygen atom protrudes into the nucleobase slot and in this conformation, would clash with the substrate were it to bind in the same manner (Fig. 2B ). To determine whether this NPP5-specific substitution prevents nucleotide hydrolysis, we assayed activity of the Y73F mutant against NTPs and NDPs ( Fig. 2C) . Substrate cleavage by the wild-type enzyme is minimal or undetectable. Strikingly, the Y73F mutation enables activity on nucleotides, with about fourfold higher rates for adenine versus uridine (Fig. 2C,  D) and no strong preference for diphosphates or triphosphates. In summary, the structural and enzymatic data indicate that the NPP5-specific Tyr-73 substitution (Fig. 2E ) prevents efficient hydrolysis of nucleoside triphosphates and diphosphates to NMPs.
In addition to NTPs and NDPs, other related nucleotides participate in extracellular signaling, including nucleotide sugars and dinucleoside polyphosphates [1] . To determine whether wild-type NPP5 is inactive against all types of nucleotides, we assayed it on several of these substrates (Fig. 3A) . No cleavage of diadenosine tetraphosphate was detected (data not shown). Interestingly, the enzyme is able to degrade ADP-ribose (ADPR) and UDP glucose (UDPG). This suggests that the protein establishes interactions with the terminal sugar moiety of these molecules. Furthermore, the highest rate was obtained on nicotinamide adenine dinucleotide (NAD + , NAD), around 1 s À1 at 1.5 mM substrate. The nicotinamide positive charge, or its amide nitrogen (Fig. 3E) , possibly contributes to favorable contacts with the enzyme, as replacement of the nicotinamide portion by nicotinic acid decreases the hydrolysis rate (NAAD, Fig. 3A,E) . These results suggest that certain nucleotides are able to overcome the nucleobase binding slot obstruction caused by Tyr-73 or that their binding mode is different from AMP in NPP1 and NPP4. We, therefore, attempted to crystallize the catalytically inactive T72A NPP5 mutant with NAD. However, the substrate likely underwent slow hydrolysis during crystallization, and only the AMP product remained in complex with the protein (soaking was also unsuccessful, and modeling approaches were ambiguous). The phosphate group of AMP is oriented closer to the active site zinc ions than what is seen in other NPPs (Fig. 3B) ; this is likely due to the T72A mutation and could be relevant to the enzyme-substrate complex, where the phosphorus atom needs to be sufficiently close to Thr-72 for a nucleophilic attack. Surprisingly, AMP is positioned with its nucleobase in the slot, similarly to the NPP4-AMP complex. The base is shifted upwards and Tyr-73 is displaced slightly downwards relative to the apo protein to prevent clashing. However, this arrangement comes at an energetic cost that greatly decreases activity against ADP and UDP (Fig. 2C) , attributed to the loss of the T-shaped p-p stacking interaction, and a misalignment leading to disruption of the parallel p-p stacking on the opposite side of the cleft. This could mean one of two possibilities: NPP5 has evolved not to bind and hydrolyze nucleotides, or the decreased affinity for the base requires more emphasis on recognition of other regions of a nucleotide substrate. Interestingly, although the determinants favoring NAD over other tested substrates remain to be elucidated, the NPP5-specific Zn3 moves closer to the substrate binding site and becomes coordinated by the 2 0 and 3 0 oxygen atoms of the ribose (Fig. 3B) .
This configuration raised the possibility that Zn3 plays an integral role in substrate recognition, as it is reminiscent of metal-mediated carbohydrate binding by C-type lectins (Fig. 3C) [24] . To evaluate the contribution of this interaction, we replaced one of the two coordinating residues by the corresponding amino acid from the NPP4 paralog (E159S; Fig. 1A) . Surprisingly, ADP and NAD hydrolysis rates were unaffected by the mutation (Fig. 3D) , indicating that Zn3 is not required for NAD cleavage by NPP5. Zinc concentration during crystallization and in activity assays was 10 lM, comparable to serum levels of 17 lM, but higher than the CSF value of 0.5 lM [25] . This suggests that the NPP5-specific metal site could be occupied at physiologically relevant zinc levels. In vertebrates, one of the metalcoordinating residues, Asp-192, is strictly conserved as aspartate or glutamate (Fig. 2G) . Glu-159, however, is preserved except in all bony fish. However, Tyr-73 is present in all vertebrates except in a subset of bony fish, where it is replaced mainly by a phenylalanine (as in NPP4). These two features could thus be evolutionarily coupled, but their roles in substrate selectivity remains unclear. Outside of the NPP family, a few trinuclear phosphodiesterases are known; in those enzymes, however, the third zinc ion is closer to the other two and participates in catalysis [26] .
Orthologs of NPP5 have also been reported in nonvertebrates. The vampire snail Colubraria reticulata secretes anticoagulants during feeding, and a protein similar to NPP5 is highly expressed in its salivary tissue [19] . In the parasitic flatworms Schistosoma mansoni and Schistosoma japonicum, which live in blood capillaries, an ortholog of NPP5 is also present, on the outer layer of the worm [20, 21] . Interestingly, SmNPP5 can hydrolyze p-nitrophenyl-TMP [20, 22] and was proposed to participate in catabolism of extracellular nucleotides [27] . However, these proteins contain a phenylalanine at the position of Tyr-73 in mammalian NPP5 (Fig. 2F) . This could explain their activity on nucleotides in the circulation, and they are, therefore, more likely to be orthologs of mammalian NPP4.
An additional function of extracellular nucleotides takes place at neuromuscular junctions and in the brain. Several adenine-based molecules including NAD possess characteristics of neurotransmitters: storage in synaptic vesicles, release upon electrical field and other stimulation, activation of postsynaptic receptors (including P2Y1 and P2X7 for NAD) causing hyperpolarization, uptake across the cell membrane, and degradation by extracellular enzymes [28] . The NADmetabolizing enzymes include CD38, BST1, 5 0 -nucleotidase [28] , and members of the NPP family [1] (in vitro, and it is not their major substrate). NPP5 displays the highest activity on NAD among the nucleotides we tested, and evidence exists for a role of this protein in neural function, as previously described, but the affinity for this substrate is low -over 1 mM (Fig. 3A) . However, NAD is also a very weak agonist of the P2Y1 receptor compared with ATP [29] . For instance, the IC 50 of NAD for inhibition of muscle contractions, by its binding to the P2Y1 receptor and hyperpolarization, is up to 2.5 mM [30] . Also, activation of the P2Y11 receptor in granulocytes by millimolar levels of NAD leads to a different response than micromolar concentrations [31] . The low affinity to NPP5 could thus be relevant in the context of purinergic receptors. This compound is secreted in comparable amounts to ATP and is present at similar levels in synaptic vesicles from PC12 cells [32] , and ATP concentrations in vesicles reaches 200 mM [33] . Therefore, NPP5 could be exposed to high local NAD levels at the cell membrane in synapses. On the other hand, the concentration of this molecule in the circulation is around 30 lM [34] , making it an unlikely NPP5 substrate in that environment.
The possibility remains that physiological substrates of this enzyme are other than nucleotides or phospholipids, the typical compounds hydrolyzed by the NPP family. In that respect, the NPP5-specific Zn3 warrants further investigation. The structures reported in this study are a step toward elucidating the functions of this poorly characterized protein.
Materials and methods
Protein expression and purification
Recombinant NPP5 was expressed as secreted protein in Sf9 insect cells infected with baculovirus. The endogenous signal peptide comprising the first 24 residues was replaced by the melittin signal peptide MKFLVNVALVFMVVYISYIYA followed by a hexahistidine tag DRHHHHHHKL. The construct encompassed residues 25-430 of the human or murine proteins (UniProt ID: Q9UJA9, UniProt ID: Q9EQG7). The last 47 residues, containing a transmembrane segment and a short cytoplasmic peptide, were excluded. All constructs and mutants were verified by sequencing. NPP5 was isolated from expression culture media using nickel-nitrilotriacetic acid (Ni-NTA) resin and further purified by size exclusion chromatography on a Superdex 200 column (GE Healthcare, Chicago, IL, USA) in buffer (15 mM Tris/HCl pH 7.5, 100 mM NaCl, 10 lM ZnCl 2 ). The enzyme eluted as a monomer and was concentrated to 10 mgÁmL À1 .
Crystallization and structure determination
Human NPP5 crystallized in 100 mM sodium MES pH 6.5 with 15% PEG 6000 and 5% MPD, and cryoprotected with 20% glycerol. The murine protein crystallized in 100 mM sodium acetate pH 4.5 with 30% PEG 200. The murine T72A mutant was co-crystallized with 10 mM NAD. Crystals were grown by sitting or hanging drop vapor diffusion at 22°C and were flash-frozen. X-ray diffraction data on the human and murine wild-type crystals were collected at 100 K on beamline 08ID-1 with a Rayonix MX300 CCD detector at the Canadian Macromolecular Crystallography Facility (CMCF), Canadian Light Source (CLS). Data on the T72A mutant crystal with NAD was collected at 100 K on beamline F1 with a Dectris Pilatus 6M detector at the Cornell High Energy Synchrotron Source (MacCHESS). Data were processed by HKL2000 [35] with auto corrections enabled. The murine wild-type structure was solved by molecular replacement with Phaser [36] in Phenix [37] using the crystal structure of NPP4 (PDB ID: 4LR2) as a search model, and re-built manually in Coot [38] . The other two structures were then solved by molecular replacement with this murine wild-type one. Refinement was carried out by phenix.refine [39] . The human structure was refined with noncrystallographic symmetry (NCS) restraints and isotropic temperature factors (no translation-libration-screw parameters). Both murine structures were refined without NCS restraints, and with anisotropic temperature factors for nonhydrogen atoms; suitability of anisotropic B factors was confirmed by the PDB_REDO server [40] . Crystallographic data collection and structure refinement statistics are presented in Table 1 . Structural images were prepared with PyMOL (The PyMOL Molecular Graphics System, Version 1.3 Schr€ odinger, LLC).
In vitro enzymatic activity assays
Purified human NPP5 at 1 nM to 1 lM was incubated in assay buffer (20 mM Tris/HCl pH 7.5, 100 mM NaCl, 10 lM ZnCl 2 ) with substrates at 1 mM (unless specified otherwise) for 1 h at 37°C. For ATP and UTP substrates, recombinant Escherichia coli inorganic pyrophosphatase (PPase) at 1 lM was included in the reaction along with 5 mM MgCl 2 to convert the pyrophosphate product to phosphate. For ADPR, UDPG, NAD, and NAAD substrates, calf intestinal phosphatase (CIP; Thermo Fisher Scientific, Waltham, MA, USA) was added at 40 UÁmL À1 for 5 min after the reaction to convert the nucleoside monophosphate products to phosphate. Four volumes of Biomol Green reagent (Enzo Life Sciences, Farmingdale, NY, USA) were added, followed by incubation for 20 min and absorbance measurement at 600 nm. Substrate hydrolysis was quantified with a phosphate standard curve, correcting for the background activity of PPase and CIP and adjusting for the fact that all substrates except ADP and UDP result in two equivalents of phosphate.
